Is monotherapy for febrile neutropenia still a viable alternative?

Clinical Infectious Diseases

Volumn 29, Issue 3, 1999, Pages 508-514

  Ramphal, Reuben ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CARBENICILLIN; CEFALOTIN; CEFEPIME; CEFPIROME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; GENTAMICIN; IMIPENEM; MEROPENEM; METICILLIN; PIPERACILLIN; POLYMYXIN; TAZOBACTAM; TOBRAMYCIN; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC RESISTANCE; CONTROLLED STUDY; FEBRILE NEUTROPENIA; GRAM NEGATIVE BACTERIUM; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0032820612     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/598623     Document Type: Review

References (42)

1. Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing veftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia, N Engl J Med 1986;315:552-8.
2. Sanders JW, Power NR, Moore RD. Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a meta-analysis. J Infect Dis 1991;164:907-16.
3. Ramphal R, Gucalp R, Rotstein C, Cimino M, Oblon D. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient. Am J Med 1996;100(suppl 6A):83S-89S.
4. Bodey GP, Whitecar JP, Middleman E, Rodriguez V. Carbenicillin therapy tor Pseudomonas infections. JAMA 1971;218:62-6.
5. Schimpff SC, Satterlce W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile neutropenic patients with cancer and granulocytopenia. N Engl J Med 1971;284:1061-5.
6. EORTC International Antimicrobial Project Group. Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. J Infect Dis 1978;137:14-29.
7. Klastersky J, Zinner SH. Synergistic combinations of antibiotics in gram-negative bacillary infections. Rev Infect Dis 1982;4:294-301.
8. de Jongh CA, Joshi JH, Newman KA, et al. Antibiotic synergism and response in gram negative bacteremia in granulocytopenic patients. Am J Med 1986;80(suppl 8C):96-111.
9. Van Laethem Y, Lagast H, Klastersky J, Serum bactericidal activity of ceftazidime and cefoperazone alone or in combination with amikacin against Pseudomonas aeruginosa and Klebsiella pneumoniae. Antimicrob Agents Chemother 1983;23:435-9.
10. Wade JC, Standiford HC, Drusano GL, et al. The potential of imipenem as single agent empiric antibiotic therapy for febrile neutropenic patients with cancer. Am J Med 1985;78(suppl 6A):62-72.
11. De Pauw BE, Kauw F, Muytjens H, et al. Randomized study of ceftazidime versus gentamicin plus cefotaxime for infections in severely granulocytopenic patients. J Antimicrob Chemother 1983;12(suppl A):93-9.
12. EORTC International Antimicrobial Therapy Cooperative Study Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia N Engl J Med 1987;317:1692-8.
13. De Pauw BE, Deresinski SC, Feld R, et al. Ceftazidime compared to piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. Ann Intern Med 1994;120:834-44.
14. Ramphal R, Bolger M, Oblon D, et al. Vancomycin is not an essential component of the initial empiric treatment regimen of febrile neutropenic patients receiving ceftazidime: a randomized comparative study. Antimicrob Agents Chemother 1992;36:1062-7.
15. Rolston KVI, Berkey P, Bodey GP, et al. A comparison of imipenem to ceftazidime with and without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 1992;152:283-91.
16. Freifeld AG, Walsh T, Marshall D, et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem, J Clin Oncol 1995;13:165-76.
17. Breen J, Ramphal R, Cometta A, et al. Cefepime versus ceftazidime as empiric therapy of febrile neutropenic patients. In: Klastersky J, ed. Febrile neutropenia. Berlin: Springer-Verlag, 1997:63-74.
18. Winston DJ, Ho WG, Bruckner DA, Champlin RE. Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med 1991;115:849-59.
19. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 1999;29:490-4.
20. Neu H. The crisis in antibiotic resistance. Science 1992;257:1064-73.
21. Rubin M, Hathorn JW, Marshall D, et al. Gram-positive infections and use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 1988;108:30-5.
22. Elting L, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case control study of predisposing factors. Clin Infect Dis 1992;14:1201-7.
23. Pizzo PA, Ladisch S, Witebsky FG. Alpha hemolytic streptococci: clinical significance in the cancer patient. Med Pediatr Oncol 1978;4:367-70.
24. Doern GV, Ferraro MJ, Brueggemann AB, Ruoff KL. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob Agents Chemother 1996;40:891-4.
25. Pfaller MA, Marshall SA, Jones RN. In vitro activity of cefepime and ceflazidime against 197 nosocomial blood stream isolates of streptococci: a multicenter sample. Diagn Microbiol Infect Dis 1997;29:273-6.
26. Carratalá J, Alcide F, Fernández-Sevilla A, et al. Bacteremia due to viridans streptococci that are highly resistant to penicillin: increase among neutropenic patients with cancer. Clin Infect Dis 1995;20:1169-73.
27. Pierard D, De Meyer A, Lauwers D, Antibiotic susceptibility of streptococcí isolated from blood from neutropenic patients. Pathol Biol (Paris) 1994;42:471-4.
28. McWhinney PMH, Patel S, Whiley RA, et al. Activities of potential therapeutic and prophylactic antibiotics against blood culture isolates of viridans group streptococci from neutropenic patients receiving ciprofloxacin. Antimicrob Agents Chemother 1993;37:2493-5.
29. Shenep JL, Hughes WT, Roberson PK, et al. Vancomycin, ticarcillin and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febríle neutropenic patients with cancer. N Engl J Med 1988;319:1053-8.
30. Rolston KVI, Raad I, Whimbey E, Bodey GP. The changing spectrum of bacterial infections in febrile neutropenic patients. In: Klastersky J, ed. Febrile neutropenia. Berlin: Springer-Verlag, 1997:53-6.
31. Maugein J, Perrier F, Cony-Makhoul P, et al. Activité in vitro de six beta-lactmines vis-à-vis de 295 souches d'enterobacteries et de P. aeruginosa isolécs chez des patients neutropeniques. Pathol Biol (Paris) 1995;43:253-7.
32. Johnson MP, Ramphal R. β-lactam-resistant Enterobacter bacteremia in febrile neutropenic patients receiving monotherapy. J Infect Dis 1990; 162:981-3.
33. Reiffers J, Makhoul-Cony P, Pris J, et al. Efficacy of cefpirome in the initial management of febrile neutropenic patients with hematologic malignancies [abstract 373]. In: Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy (Anaheim, CA). Washington, DC: American Society for Microbiology, 1992.
34. Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1996;40:1108-15.
35. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. J Antimicrob Chemother 1995; 36:185-200.
36. Klugman K, Goldstein F, Kohno S, et al. The role of fourth generation cephalosporins in the treatment of infections caused by penicillin-resistant streptococci. Clin Microbiol Infect 1997;3(suppl 1):S48-60.
37. Kessler RE, Fung-Tome J. Susceptibility of bacterial isolates to β-lactam antibiotics from US clinical trials over a 5-year period. Am J Med 1996;100(suppl 6A):13S-9S.
38. Cometta A, Zinner S, de Bock R, et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1995;39:445-52.
39. Yamamura D, Gucalp R, Carlisle P, et al. Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients. Antimicrob Agents Chemother 1097;41:1704-8.
40. Immunocompromised Host Society. Design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. J Infect Dis 1990;161:397-401.
41. Hughes WT, Armstrong D, Bodey GP, et al. 1997 guidelines for the use of antimicrobial agents in neutropcnic patients with unexplained fever. Clin Infect Dis 1997;25:551-73.
42. Rolston KVI. New trends in patient management: risk-based therapy for febrile patients with neutropenia. Clin Infect Dis 1999;29:515-21.